中文 | English
Return
Total: 6 , 1/1
Show Home Prev Next End page: GO
MeSH:(Anaplastic Lymphoma Kinase/therapeutic use*)

1.Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC.

Wei RAO ; Yutao LIU ; Yan LI ; Lei GUO ; Tian QIU ; Lin DONG ; Jianming YING ; Weihua LI

Frontiers of Medicine 2023;17(3):493-502

2.A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.

Wenjia SUN ; Jing ZHENG ; Jianya ZHOU ; Jianying ZHOU

Journal of Zhejiang University. Medical sciences 2023;52(5):583-587

3.Treatment of ALK Positive Non-small Cell Lung Cancer with Alectinib: 
A Case Report and Literature Review.

Haixiang YANG ; Wei ZHU

Chinese Journal of Lung Cancer 2021;24(9):673-676

4.Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer.

Peng SONG ; Li ZHANG ; Congcong SHANG

Chinese Journal of Lung Cancer 2018;21(9):703-711

5.Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation 
Treated with Ensartinib: A Case Report and Literature Review.

Donglai LV ; Chunwei XU ; Chong WANG ; Qiuju SANG

Chinese Journal of Lung Cancer 2023;26(1):78-82

6.Advanced Pneumonic-type Lung Carcinoma: A Retrospective Study of Clinical-radiological-pathological Characteristics with Survival Analysis in A Single Chinese Hospital.

Yongjian LIU ; Ji LI ; Shibo WANG ; Minjiang CHEN ; Jing ZHAO ; Delina JIANG ; Wei ZHONG ; Yan XU ; Mengzhao WANG

Chinese Journal of Lung Cancer 2019;22(6):329-335

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 6 , 1/1 Show Home Prev Next End page: GO